{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:41:20Z","timestamp":1762987280506,"version":"3.45.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtocrr.2022.100351","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T22:54:55Z","timestamp":1654815295000},"page":"100351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report"],"prefix":"10.1016","volume":"3","author":[{"given":"Takaaki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-0433","authenticated-orcid":false,"given":"Nobukazu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2022.100351_bib1","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2022.100351_bib2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/med.21478","article-title":"Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: what we know, what we do not know, and what we can do to prevent adverse effects","volume":"38","author":"Spallarossa","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jtocrr.2022.100351_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejca.2017.08.014","article-title":"Challenges and perspectives in the immunotherapy of Hodgkin lymphoma","volume":"85","author":"Michot","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2022.100351_bib4","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtocrr.2022.100351_bib5","article-title":"Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma","volume":"31","author":"Sakakibara-Konishi","year":"2020","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jtocrr.2022.100351_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2022.100351_bib7","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2022.100351_bib8","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"CONFIRM Trial Investigators. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2022.100351_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2022.100351_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364322000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:37:23Z","timestamp":1762987043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364322000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2666364322000753"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100351","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100351"}}